Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study

OBJECTIVE: To investigate the long-term safety and efficacy of weekly subcutaneous IgPro20 (Hizentra, CSL Behring) in chronic inflammatory demyelinating polyneuropathy (CIDP). METHODS: In a 48-week open-label prospective extension study to the PATH study, patients were initially started on 0.2 g/kg...

Descripción completa

Detalles Bibliográficos
Autores principales: van Schaik, Ivo N., Mielke, Orell, Bril, Vera, van Geloven, Nan, Hartung, Hans-Peter, Lewis, Richard A., Sobue, Gen, Lawo, John-Philip, Praus, Michaela, Durn, Billie L., Cornblath, David R., Merkies, Ingemar S. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624149/
https://www.ncbi.nlm.nih.gov/pubmed/31355323
http://dx.doi.org/10.1212/NXI.0000000000000590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624149/
https://www.ncbi.nlm.nih.gov/pubmed/31355323
http://dx.doi.org/10.1212/NXI.0000000000000590

Ejemplares similares